From Bipolar to Unipolar: Lumateperone FDA Approved as Adjunct for MDD
Lumateperone is an oral, once-daily atypical antipsychotic developed by Intra‑Cellular Therapies (later acquired by Johnson & Johnson). Initially approved in the U.S. in December 2019…